Clinical Trials
|
Disease |
Chronic
Plaque Psoriasis |
|
Title |
Phase 1/2a, ascending multiple dose
study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and
clinical efficacy of an investigational medication administered
subcutaneously to subjects with psoriasis. |
|
Inclusion* |
Stable plaque psoriasis for at
least 6 months |
|
Study Contact |
email: aieska.souza@nyumc.org |
|
Principal Investigator |
Name: Dr. Bruce E. Strober |
|
Objective |
To evaluate the clinical effect of
an investigational medication on psoriasis activity as defined by change in
the psoriasis area and severity index score, target lesion score, and the
physician global assessment of psoriasis score |
|
Status |
Recruitment will start soon |
|
Age Requirement |
≥ 18 years of age |
|
Gender |
males and females (post-menopausal
or non-childbearing potential) |
|
Disease |
Chronic
Plaque Psoriasis |
|
Title |
Phase 1, randomized,
double-blind, placebo-controlled, ascending dose study to assess the
safety, tolerability, pharmacokinetics, and pharmacodynamics of a new
medication following a single intravenous or subcutaneous administration in
healthy subjects and in subjects with moderate to severe psoriasis. |
|
Inclusion* |
Stable plaque psoriasis for at
least 6 months |
|
Study Contact |
email: aieska.souza@nyumc.org |
|
Principal Investigator |
Name: Dr. Bruce E. Strober |
|
Objective |
To evaluate the safety and efficacy
of a new treatment |
|
Status |
Recruitment will start soon |
|
Age Requirement |
≥ 18 years of age |
|
Gender |
males and females (post-menopausal
or non-childbearing potential) |
|
Disease |
Chronic
Plaque Psoriasis |
|
Title |
Multi-center, open registry of
patients with psoriasis who are candidates for systemic therapies including
biologics. |
|
Inclusion* |
Patients with all forms of
psoriasis receiving systemic therapy |
|
Study Contact |
email: aieska.souza@nyumc.org |
|
Principal Investigator |
Name: Dr. Bruce E. Strober |
|
Objective |
Evaluate the safety and efficacy of
a systemic medication |
|
Status |
Recruiting |
|
Age Requirement |
≥ 18 years of age |
|
Gender |
males and females |
|
Disease |
Chronic
Cutaneous Lupus Erythematosus |
|
Title |
Clinical and immune-modulating
effects of an investigational oral medication in discoid lupus erythematosus |
|
Inclusion* |
Men and women, who are 18 years of
age or older with a biopsy-proven diagnosis of cutaneous discoid lupus. No
evidence of systemic lupus (involvement of internal organs and/or
inflammation of blood vessels or joints). |
|
Study Contact |
email: aieska.souza@nyumc.org |
|
Principal Investigator |
Name: Dr. Andrew G. Franks |
|
Objective |
To evaluate the clinical response
of discoid lupus patients to an investigational oral medication |
|
Status |
Recruiting |
|
Age Requirement |
≥ 18 years of age |
|
Gender |
males and females |
|
Disease |
Hidradenitis
Suppurativa |
|
Title |
Phase 2, randomized, double-blind,
placebo controlled, multi-center trial to evaluate the safety and efficacy of
Adalimumab in subjects with moderate to severe chronic hidradenitis
suppurativa. |
|
Inclusion* |
Adults with hidradenitis
suppurativa for at least 6 months |
|
Study Contact |
email: aieska.souza@nyumc.org |
|
Principal Investigator |
Name: Dr. Jerome Shupack |
|
Objective |
To determine the efficacy and
safety after 16 and 36 weeks of treatment |
|
Status |
Recruiting |
|
Age Requirement |
18 years or older |
|
Gender |
males and females |
Disease | Vitiligo |
Title | Development and validation of a health-related quality of life instrument for vitiligo |
Inclusion* | Diagnosis of vitiligo |
Study Contact | Name: Dr. Roopal Kundu Phone: (212) 263-8281 |
Principal Investigator | Name: Dr. Roopal Kundu |
Objective | The purpose of this study is to develop a questionnaire that will allow physicians and researchers to better understand and quantify the effects of having vitiligo on quality of life. |
Status | Recruiting |
Age Requirement | ≥ 18 years of age |
Gender | males and females |
